Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
about
Carbamazepine overdose after exposure to simethicone: a case reportThe effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteersPharmaceutical Management of Trigeminal Neuralgia in the ElderlyCYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvementPotential fluconazole-induced carbamazepine toxicityPharmacoepidemiologic investigation of clonazepam relative clearance by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients.Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreSummary of information on human CYP enzymes: human P450 metabolism data.The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulationThe transcriptional regulation of the human CYP2C genesRelative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducersMethylxanthines, seizures, and excitotoxicity.Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness.Time Course of the Changes in Novel Trioxane Antimalarial 99/411 Pharmacokinetics upon Antiepileptic Drugs Co-Administration in SD Rats.A mechanistic approach to antiepileptic drug interactions.Potential interaction between ritonavir and carbamazepine.Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elementsThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment.What works for delirious catatonic mania?The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania.The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder.Use of antiepileptic drugs for hyperkinetic movement disorders.Hepatic proteome analysis of Atlantic salmon (Salmo salar) after exposure to environmental concentrations of human pharmaceuticals.Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015.Lamotrigine Versus Pregabalin in the Management of Refractory Trigeminal Neuralgia: A Randomized Open Label Crossover Trial.Collaboration in the presence of cerebral edema: The complications of steroids.Heart and mind: (2) psychotropic and cardiovascular therapeutics.Drug bioactivation, covalent binding to target proteins and toxicity relevance.SCN1A and SCN1B gene polymorphisms and their association with plasma concentrations of carbamazepine and carbamazepine 10, 11 epoxide in Iranian epileptic patientsMechanism of drug-drug interactions mediated by human cytochrome P450 CYP3A4 monomerThe Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs.Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendationInteraction of carbamazepine with herbs, dietary supplements, and food: a systematic reviewPrescription of psychoactive drugs in patients attended by the SUS at Manhuaçu - MG (Brazil).Application of mechanism-based CYP inhibition for predicting drug-drug interactions.Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype.
P2860
Q21202119-656E6305-1584-4DFA-954E-1E601866AFBAQ24564995-5CDAC3CA-FD6F-48AE-A3F7-11C6D3BD7BDCQ26785933-6B439E0B-5245-4351-A574-3BFC08B49B17Q28239473-5B27FF3C-EC51-457C-A9C6-7B012CC3259CQ28371958-0EFAFBD6-303B-47B5-8A24-7B4727DF3B3DQ30670879-8A0FD6F7-D824-498D-BC22-2E66866AD124Q30728586-DDC9BD0B-8B3D-4380-93F6-026FEC27F168Q31121202-938744FD-20C3-45D6-BD8D-EB6870EAC108Q32103802-0D980C33-E110-4310-9E32-3F8278669B98Q33571434-B0D4BF76-9DD3-453E-A3BE-49A4B4BD850EQ33597311-A021141F-F90A-4CD0-9E7B-6753D389C842Q33881813-182C4D43-C66C-4A70-ACED-A1B85311B6DDQ34154555-D8FCE43D-BD1E-48F6-88A2-5C70EB13D37BQ34185669-66FBF7D3-B739-4980-A0E4-0E1BC7732749Q34419498-F43E4E46-B8BB-4DE0-95BE-14D5A7B923F1Q34469990-BF06025B-820B-4B0F-B6D4-55649550458DQ34509811-EBF600DD-EEB3-4EF0-8752-927B9348C8DBQ34547632-F9913EFA-BBBE-4C33-B591-F2784871B160Q34550618-E4EC9E8B-4A5F-4EFA-8906-26E27A4270DBQ34554377-561A6218-6B9F-4C4B-9793-405A468C2F74Q34606256-3EBD92E9-63AB-42FC-ACD8-995C34458C84Q34616633-98066675-CED6-4BD5-98BD-56B38EE924EDQ34649187-A9669143-6096-45D6-AFE2-416B0250C95EQ34829294-4ACC6BD5-2E18-4409-A177-CEF82C785549Q35148568-91609D33-51AD-462F-BDBF-5D94D776830EQ35166632-B07D1D3B-DE2D-4035-A7D4-1C04AADFB45BQ35560309-6C54DA4E-505A-4236-8E71-4E97F5373CD9Q35899675-AC4E4D11-62FA-400D-AC44-D26221992A32Q35999184-A024A992-7E4C-4095-A509-6BA5C13B65CBQ36003999-CB5330F4-1634-41DD-89CC-E760A958F5B0Q36061821-0DA1EDC3-C35B-4E04-8C01-8E387B401590Q36553123-6AD003EA-F36F-4354-B3CB-D9478898243AQ36590427-0379DE9A-DE6E-4E4E-A1A1-5F859C4E6137Q36825752-B2F35D4D-191F-4472-AD34-D8DED4958226Q36871056-4330147B-471F-43CE-A27F-70F642BB9D93Q36896981-9AB80C02-3271-4913-AF81-7A7D274CB694Q37139662-C02753DA-A24F-4674-BA88-BE983E2029ABQ37283169-A6BB3132-18A9-4945-AC7A-D87F13B69604Q37494640-6E1ED889-EDD1-456F-BDEC-9122F4D3BCD9Q37547290-0A86FA20-5294-4897-8C98-2B64221F7A6E
P2860
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
@ast
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
@en
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
@nl
type
label
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
@ast
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
@en
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
@nl
prefLabel
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
@ast
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
@en
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
@nl
P2093
P1476
Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.
@en
P2093
P304
P356
10.2165/00003088-199631030-00004
P577
1996-09-01T00:00:00Z
P6179
1043267695